Table 1 Characteristics of individuals exposed and not exposed to ETR + PI contributing to follow-up, measured in number of persons-years
All patients (person-years) | All patients | No ETR + PI | ETR + PI | p |
|---|---|---|---|---|
13,985.68 | 11,666.71 | 2318.96 | ||
Age at baseline | ||||
18–29 years | 333.96 (2.4%) | 286.02 (2.5%) | 47.94 (2.1%) | < 0.0001 |
30–39 years | 3050.51 (21.8%) | 2699.57 (23.1%) | 350.94 (15.1%) | |
40–59 years | 9754.3 (69.7%) | 7973.02 (68.3%) | 1781.28 (76.8%) | |
>=60 years | 846.91 (6.1%) | 708.10 (6.1%) | 138.81 (6.0%) | |
Gender and transmission group | ||||
Men who have sex with men | 5462.59 (39.1%) | 4392.05 (37.6%) | 1070.41 (46.2%) | < 0.0001 |
Injecting drug users | 2393.23 (17.1%) | 2087.84 (17.9%) | 305.39 (13.2%) | |
Other men | 2788.01 (19.9%) | 2258.16 (19.4%) | 529.94 (22.8%) | |
Other women | 3341.84 (23.9%) | 2928.67 (25.1%) | 413.17 (17.8%) | |
Geographic origin | ||||
Sub-Saharan Africa | 1218.56 (8.7%) | 970.62 (8.3%) | 247.94 (10.7%) | 0.0002 |
Other | 12,767.12 (91.3%) | 10,696.10 (91.7%) | 2071.02 (89.3%) | |
HCV co-infection status | ||||
No | 11,650.70 (83.3%) | 9643.24 (82.7%) | 2007.47 (86.6%) | < 0.0001 |
Yes | 2334.96 (16.7%) | 2023.47 (17.3%) | 311.49 (13.4%) | |
Centre - Total follow-up of heavily treated individuals | ||||
< 140 P-Y | 2575.17 (18.4%) | 2118.09 (18.2%) | 457.02 (19.7%) | < 0.0001 |
140–240 P-Y | 3254.79 (23.3%) | 2717.26 (23.3%) | 537.53 (23.2%) | |
240–400 P-Y | 3895.42 (27.9%) | 3354.69 (28.8%) | 540.73 (23.3%) | |
≥ 400 P-Y | 4260.31 (30.5%) | 3476.68 (29.8%) | 783.63 (33.8%) | |
Calendar period | ||||
2005–2006 | 8760.93 (62.6%) | 8517.74 (73.0%) | 243.19 (10.5%) | < 0.0001 |
2007–2008 | 3779.28 (27.0%) | 2280.19 (19.5%) | 1499.09 (64.6%) | |
2009–2011 | 1445.46 (10.3%) | 868.78 (7.4%) | 576.68 (24.9%) | |
Nadir CD4 count (cells/mm3) at baseline | ||||
< 50 | 5090.31 (36.4%) | 3973.69 (34.1%) | 1116.62 (48.2%) | < 0.0001 |
50–100 | 2395.85 (17.1%) | 1989.13 (17.0%) | 406.72 (17.5%) | |
100–200 | 3564.30 (25.5%) | 3075.84 (26.4%) | 488.46 (21.1%) | |
≥ 200 | 2935.22 (21.0%) | 2628.05 (22.5%) | 307.16 (13.2%) | |
CD4 count (cells/mm3) at baseline | ||||
< 200 | 4879.74 (34.9%) | 3871.50 (33.2%) | 1008.24 (43.5%) | < 0.0001 |
200–350 | 4083.24 (29.2%) | 3521.03 (30.2%) | 562.21 (24.2%) | |
350–500 | 2537.01 (18.1%) | 2173.42 (18.6%) | 363.59 (15.7%) | |
≥ 500 | 2485.68 (17.8%) | 2100.76(18.0%) | 384.92 (16.6%) | |
VL (copies/mL) at baseline | ||||
50–500 | 2824.38 (20.2%) | 2301.04 (19.7%) | 523.34 (22.6%) | < 0.0001 |
500–5000 | 3255.58 (23.3%) | 2763.23 (23.7%) | 492.35 (21.2%) | |
5000–30,000 | 2930.25 (21.0%) | 2408.75 (20.6%) | 521.50 (22.5%) | |
30,000–100,000 | 2501.51 (17.9%) | 2059.86 (17.7%) | 441.65 (19.0%) | |
> 100,000 | 2473.97 (17.7%) | 2133.85 (18.3%) | 340.12 (14.7%) | |
Previous AIDS defining events at baseline | ||||
No | 8274.24 (59.2%) | 7116.34 (61.0%) | 1157.90 (49.9%) | < 0.0001 |
Yes | 5711.44 (40.8%) | 4550.31 (39.0%) | 1161.06 (50.1%) | |
Prophylaxis (Cotrimoxazole, Dapsone, Pentamidine) | ||||
Not eligible (CD4 > 200) | 8093.10 (57.9%) | 6969.47 (59.7%) | 1123.63 (48.5%) | < 0.0001 |
No | 1821.36 (13.0%) | 1378.35 (11.8%) | 443.01 (19.1%) | |
Yes | 4071.22 (29.1%) | 3318.89 (28.5%) | 752.33 (32.4%) | |
Number of prior ARVs | ||||
5–8 | 3749.64 (26.8%) | 3609.96 (30.9%) | 139.69 (6.0%) | < 0.0001 |
9–10 | 3816.28 (27.3%) | 3520.84 (30.2%) | 295.44 (12.7%) | |
11–13 | 4084.10 (29.2%) | 3281.11 (28.1%) | 802.99 (34.6%) | |
> 13 | 2335.66 (16.7%) | 1254.81 (10.8%) | 1080.85 (46.6%) | |